Fair Market Value Survey 2026

Fair Market Value

There is an increasing desire for patient organisations to work in partnership with pharmaceutical companies and research organisations to embed the patient voice in the medicines lifecycle.

In 2023, a group of patient organisation leaders came together to survey patient organisations’ experience of fair market value arrangements and partnerships with industry funders.

Our 2023 survey found room for improvement and resulted in the publication of a report Towards Fairer Market Value, published September 2024. https://pifonline.org.uk/resources/fair-market-value-for-charities-in-partnership-work/

The report and recommendations built on the recommendations of a report from Arthritis UK and partners, Transactional to truly collaborative https://www.arthritis-uk.org/media/25664/improving-relationships-industry-patient-report.pdf

In 2025, PIF partnered with the ABPI to update the handbook on partnership working between and patient organisations. https://www.abpi.org.uk/publications/working-together-a-handbook-for-industry-and-patient-organisation-partnerships-2025/

In 2026 we are repeating the survey

The aim of doing this is to:

Measure the impact of the report Towards Fairer Market Value

Identify other pressures impacting partnerships between industry and patient organisations.

To include some themes from the Arthritis UK research

Thank you for taking the time to complete the survey.

If you have any comments about this piece of work please contact: info@pifonline.org.uk

For your chance to win a £30 Amazon voucher, remember to include your email address at the end.

1.Name of charity or organisation

3.Do you provide information and support?(Required.)

Yes

6.What health condition(s) do you cover?

Please tick all that apply.(Required.)

Other (please specify)

7.How many pharmaceutical companies and/or their agencies have you worked with in the past year?(Required.)

Up to 5

5 - 10

More than 10

9.Please give us examples of key projects or activities where you are/have worked with companies during these stages of the medicines development process.

10.Thinking about the way you usually work with companies, please select which statement most applies to your organisation.

We usually work with them for ‘one off’ type interactions (e.g. a focus group meeting)

We have established relationships with them and are regularly consulted or exchange information (e.g. regular update calls/meetings with a named contact to discuss potential areas of work or to give and receive updates)

We have long term relationships with them, where we co-create projects/plans (e.g. long term, strategic planning/collaborations or jointly planning, delivering, evaluating a project)

11.Do pharmaceutical companies and their agencies define ‘fair market value’ for your time?

Yes

Yes, but varies what the company offers as ‘their’ FMV

12.Do you think FMV is consistent company to company?(Required.)

Yes

Not sure

13.Do you think FMV rates have improved since we published our report and recommendations Towards Fairer Market Value in September 2024?(Required.)

Yes

Not sure

14.Do you think contracting arrangements have been simplified since we published our report and recommendations towards Fairer Market Value in September 2024?(Required.)

Yes

Not sure

15.If no, please can you identify on-going concerns.

Please select all that apply.

Other (please specify)

16.Recent PMCPA code cases have reinforced the code requirement on declaration of funding. This has caused concern from patient organisations about how these are applied to digital projects. Do you share these concerns?

Please select all that apply.(Required.)

Prominence of funding statements on smart phone screens, creates a barrier to people and search engines accessing content.

Prominence of funding statements is out of proportion relative to the amount of funding provided.

Prominence of funding statements implies content has been directly influenced by the funder.

Lack of clarity over how long funding statements need to stay in place, for example post content review.

Requests that funding declarations should sit on every linked page of content from a main website page.

17.Do you support the principal of transparency on industry funding?

Yes, and we support current rules on declarations

Yes, but we need to find a practical way to do this on digital platforms

No, declarations should only sit alongside content that industry has influenced

18.What has worked well when working with companies (i.e. the practicalities, process of engagement and/or in the relationship)?

19.Are there any other areas causing tensions in industry and patient organisation partnerships?

20.In your view, what could companies do to make it easier for you to work with them?

21.What kind of projects would you like to work with companies on in the future?

22.Thank you for your feedback. For your chance to win a £30 Amazon voucher, please add your email address.